{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Thyroid+Gland+Follicular+Carcinoma", "query": { "condition": "Refractory Thyroid Gland Follicular Carcinoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 19, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Thyroid+Gland+Follicular+Carcinoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-10T18:28:31.521Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04544111", "title": "PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thyroid Cancer", "Thyroid Cancer, Follicular", "Papillary Thyroid Cancer", "Follicular Thyroid Cancer", "Hurthle Cell Tumor", "Poorly Differentiated Thyroid Gland Carcinoma", "Hurthle Cell Thyroid Neoplasia" ], "interventions": [ { "name": "Trametinib", "type": "DRUG" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "PDR001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2020-09-02", "completion_date": "2026-09-02", "has_results": false, "last_update_posted_date": "2025-10-07", "last_synced_at": "2026-06-10T18:28:31.521Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04544111" }, { "nct_id": "NCT01811212", "title": "Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Poorly Differentiated Thyroid Gland Carcinoma", "Recurrent Thyroid Gland Carcinoma", "Stage I Thyroid Gland Follicular Carcinoma", "Stage I Thyroid Gland Papillary Carcinoma", "Stage II Thyroid Gland Follicular Carcinoma", "Stage II Thyroid Gland Papillary Carcinoma", "Stage III Thyroid Gland Follicular Carcinoma", "Stage III Thyroid Gland Papillary Carcinoma", "Stage IVA Thyroid Gland Follicular Carcinoma", "Stage IVA Thyroid Gland Papillary Carcinoma", "Stage IVB Thyroid Gland Follicular Carcinoma", "Stage IVB Thyroid Gland Papillary Carcinoma", "Stage IVC Thyroid Gland Follicular Carcinoma", "Stage IVC Thyroid Gland Papillary Carcinoma", "Tall Cell Variant Thyroid Gland Papillary Carcinoma", "Thyroid Gland Oncocytic Follicular Carcinoma" ], "interventions": [ { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2013-05-08", "completion_date": "2017-10-09", "has_results": true, "last_update_posted_date": "2018-04-03", "last_synced_at": "2026-06-10T18:28:31.521Z", "location_count": 7, "location_summary": "Washington D.C., District of Columbia • Jacksonville, Florida • Chicago, Illinois + 4 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01811212" }, { "nct_id": "NCT00026533", "title": "Thalidomide in Treating Patients With Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kenneth Ain", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "2001-06", "completion_date": "2005-12", "has_results": false, "last_update_posted_date": "2017-06-06", "last_synced_at": "2026-06-10T18:28:31.521Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT00026533" }, { "nct_id": "NCT05668962", "title": "Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thyroid Cancer", "Thyroid Carcinoma", "Metastatic Thyroid Cancer", "Follicular Thyroid Cancer", "Unresectable Thyroid Gland Carcinoma", "Papillary Thyroid Cancer" ], "interventions": [ { "name": "Selpercatinib", "type": "DRUG" }, { "name": "Sodium Iodine I-131", "type": "DRUG" }, { "name": "rhTSH", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 30, "start_date": "2023-03-01", "completion_date": "2026-01-01", "has_results": false, "last_update_posted_date": "2024-12-12", "last_synced_at": "2026-06-10T18:28:31.521Z", "location_count": 6, "location_summary": "Washington D.C., District of Columbia • Tampa, Florida • Boston, Massachusetts + 3 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05668962" }, { "nct_id": "NCT03914300", "title": "Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Differentiated Thyroid Gland Carcinoma", "Follicular Variant Thyroid Gland Papillary Carcinoma", "Poorly Differentiated Thyroid Gland Carcinoma", "Refractory Differentiated Thyroid Gland Carcinoma", "Refractory Thyroid Gland Carcinoma", "Tall Cell Variant Thyroid Gland Papillary Carcinoma", "Thyroid Gland Follicular Carcinoma", "Thyroid Gland Oncocytic Carcinoma", "Thyroid Gland Papillary Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2020-02-10", "completion_date": "2026-12-17", "has_results": true, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-06-10T18:28:31.521Z", "location_count": 33, "location_summary": "Duarte, California • Los Angeles, California • Newport Beach, California + 25 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03914300" }, { "nct_id": "NCT02973997", "title": "Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Columnar Cell Variant Thyroid Gland Papillary Carcinoma", "Follicular Variant Thyroid Gland Papillary Carcinoma", "Metastatic Thyroid Gland Follicular Carcinoma", "Metastatic Thyroid Gland Papillary Carcinoma", "Poorly Differentiated Thyroid Gland Carcinoma", "Recurrent Differentiated Thyroid Gland Carcinoma", "Recurrent Thyroid Gland Follicular Carcinoma", "Recurrent Thyroid Gland Papillary Carcinoma", "Stage III Differentiated Thyroid Gland Carcinoma AJCC v7", "Stage III Thyroid Gland Follicular Carcinoma AJCC v7", "Stage III Thyroid Gland Papillary Carcinoma AJCC v7", "Stage IV Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IV Thyroid Gland Papillary Carcinoma AJCC v7", "Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7", "Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7", "Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7", "Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7", "Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7", "Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7", "Tall Cell Variant Thyroid Gland Papillary Carcinoma", "Thyroid Gland Hurthle Cell Carcinoma", "Unresectable Differentiated Thyroid Gland Carcinoma", "Unresectable Thyroid Gland Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Lenvatinib Mesylate", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "DRUG", "BIOLOGICAL" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2018-02-07", "completion_date": "2023-10-08", "has_results": true, "last_update_posted_date": "2025-08-29", "last_synced_at": "2026-06-10T18:28:31.521Z", "location_count": 7, "location_summary": "Torrance, California • Aurora, Colorado • Boston, Massachusetts + 4 more", "locations": [ { "city": "Torrance", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02973997" }, { "nct_id": "NCT00098813", "title": "Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Thyroid Cancer", "Stage IV Follicular Thyroid Cancer", "Stage IV Papillary Thyroid Cancer" ], "interventions": [ { "name": "romidepsin", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "positron emission tomography", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2004-10", "completion_date": "2009-08", "has_results": true, "last_update_posted_date": "2014-05-28", "last_synced_at": "2026-06-10T18:28:31.521Z", "location_count": 1, "location_summary": "Commack, New York", "locations": [ { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00098813" }, { "nct_id": "NCT01413113", "title": "Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Thyroid Cancer", "Stage IVA Follicular Thyroid Cancer", "Stage IVA Papillary Thyroid Cancer", "Stage IVB Follicular Thyroid Cancer", "Stage IVB Papillary Thyroid Cancer", "Stage IVC Follicular Thyroid Cancer", "Stage IVC Papillary Thyroid Cancer" ], "interventions": [ { "name": "pazopanib hydrochloride", "type": "DRUG" }, { "name": "iodine I 131", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2011-12", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2015-11-05", "last_synced_at": "2026-06-10T18:28:31.521Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01413113" }, { "nct_id": "NCT00559949", "title": "Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Thyroid Gland Carcinoma", "Stage I Thyroid Gland Papillary Carcinoma", "Stage II Thyroid Gland Papillary Carcinoma", "Stage III Thyroid Gland Papillary Carcinoma", "Stage IV Thyroid Gland Papillary Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Selumetinib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2007-12", "completion_date": "2016-08", "has_results": true, "last_update_posted_date": "2017-01-30", "last_synced_at": "2026-06-10T18:28:31.521Z", "location_count": 5, "location_summary": "Tampa, Florida • Chicago, Illinois • Chapel Hill, North Carolina + 2 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00559949" }, { "nct_id": "NCT00287287", "title": "REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thyroid Neoplasms" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kenneth Ain", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2006-02", "completion_date": "2010-07-06", "has_results": true, "last_update_posted_date": "2020-06-12", "last_synced_at": "2026-06-10T18:28:31.521Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT00287287" } ] }